- In July 2024, Perosphere Technologies, a developer of advanced coagulation diagnostics, has entered into an exclusive distribution agreement with CoRRect Medical for its point-of-care (PoC) coagulometer in Germany. Perosphere’s PoC coagulometer is a reagent-free, pharmacodynamic diagnostic device designed to enable quick assessment of coagulation status. It aids in making informed treatment decisions for patients on anticoagulant therapies, including direct oral anticoagulants (DOACs)
- In July 2024, Roche has finalized its previously announced acquisition of LumiraDx's Point of Care technology for up to USD 350 million. This acquisition, completed after obtaining all necessary antitrust and regulatory approvals, represents a substantial enhancement of Roche's diagnostics portfolio
- In March, 2024, SpinChip Diagnostics has created a compact immunoassay point-of-care (PoC) analyzer that provides diagnostic performance comparable to that of advanced laboratory instruments, using just a droplet of blood and delivering results within minutes. The platform is scalable and has the potential to emerge as one of the most comprehensive testing solutions in the PoC market
- In July 2023, Anbio Biotechnology Ltd. has introduced the Anbio AF-100S, an automated, compact, and cost-effective fluorescent immunoassay (FIA) solution aimed at revolutionizing clinical diagnostics and empowering healthcare providers. The AF-100S FIA is a handheld point-of-care immunodiagnostic tool that delivers rapid, accurate, and reliable results for a variety of analytes
